Compare IOP Reduction

15 products »

close Created with Sketch.

Vyzulta

Bausch + Lomb Inc.

Vyzulta (latanoprostene bound ophthalmic solution 0.024%), is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Vyzulta is the first prostaglandin analog with one of its metabolites being nitric oxide (NO).

At-a-Glance
  • Mechanism of Action: Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.
  • Dosage: One drop in the affected eye(s) once daily in the evening.

Details

FDA

Yes

CE Mark

Yes

Active Ingredients

Latanoprostene bunod

Application

Topical

Status

Prescription

Strength

0.024%

From Your Peers

Options Expanding for IOP Lowering

READ ARTICLE »

Company Information

Contact the company for additional information, availability, or pricing:

Bausch + Lomb Inc.

bausch.com

400 Somerset Corporate Blvd.

Bridgewater, NJ 08807